Cue Biopharma Inc Stock Price, News & Analysis

Cue Biopharma (Nasdaq: CUE) announced that the FDA has granted Fast Track designation to its lead drug candidate, CUE-101, for treating HPV16+ recurrent/metastatic head and neck squamous cell carcinoma. This designation highlights the urgent need for targeted therapies in this patient population. CUE-101 has shown favorable tolerability and initial anti-tumor activity in clinical trials, and a registrational trial for monotherapy is anticipated by mid-2023. The Fast Track process may allow for expedited development and review of the drug.

Cue Biopharma (CUE) is set to present at two scientific conferences this September. The first event, The Promise of Interleukin-2 Therapy, runs from September 14-17 in Paris. Matteo Levisetti, M.D. will present data on CUE-101, targeting HPV+ recurrent/metastatic head and neck cancer. The second event, Next Generation Protein Therapeutics Summit, takes place September 28-30 in Boston, where Anish Suri, the company’s CSO, will highlight the Immuno-STAT platform and its IL-2 based candidates. These advancements reflect Cue Biopharma’s commitment to innovative cancer therapies.

Cue Biopharma (CUE) has initiated a Phase 1 dose escalation study for CUE-102, targeting WT1-positive recurrent/metastatic cancers. The first patient has been dosed with a starting dose of 1 mg/kg, reflecting a step forward in demonstrating the Immuno-STAT™ platform's potential. CUE-102 shows promise in selectively activating tumor-specific T cells, with preclinical studies indicating significant immune response. The trial aims to enroll around 50 patients and examines safety, tolerability, and anti-tumor activity.

Cue Biopharma reported its second quarter 2022 financial results, highlighting a significant decrease in collaboration revenue to $26,000, down from $2.7 million in Q2 2021. Research and development expenses rose to $9.6 million, while general and administrative expenses fell to $3.8 million. The company extended its cash runway with $23.6 million raised from an equity offering. Notably, the FDA accepted an IND for CUE-102, and a Phase 1 trial is underway, focusing on various cancers.

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma (Nasdaq: CUE) announced its participation in the Guggenheim I&I Spotlight Series on Treg-based Therapies, scheduled for July 13, 2022, from 9:00 a.m. to 9:45 a.m. EDT. This event highlights the company's innovative approach to cancer treatment through its Immuno-STAT™ platform, which modulates T cells within the body. A live and archived webcast will be available on Cue Biopharma's website.

For more details, visit www.cuebiopharma.com.

Cue Biopharma (Nasdaq: CUE) announced participation in a fireside chat at the JMP Securities Life Sciences Conference on June 16, 2022. The presentation will focus on ongoing clinical trials and corporate development initiatives. The event will be webcast live from 1:00 p.m. to 1:25 p.m. EDT and archived for 30 days. Cue Biopharma is known for its innovative Immuno-STAT™ platform, aimed at targeted T cell engagement for cancer treatment. The company is headquartered in Boston and focuses on developing injectable biologics.

Cue Biopharma announced its participation in the Jefferies Healthcare Conference scheduled for June 8-10, 2022. The company will present updates on its lead candidate, CUE-101, currently in a Phase 1b trial for HPV16+ head and neck cancer, and its second candidate, CUE-102, which received FDA approval for an IND application. CUE-102 will undergo Phase 1 trials for WT1-positive cancers. The presentation is set for June 10 at 1:45 p.m. EDT, with webcasts available for 30 days.

BOSTON, May 26, 2022 – Cue Biopharma (Nasdaq: CUE) announced a poster presentation at the ASCO Annual Meeting from June 3-7 in Chicago. The poster will showcase interim clinical data on CUE-101, an IL-2-based therapeutic for recurrent/metastatic HPV16+ head and neck cancer, both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). The presentation is scheduled for June 6, 2022, by Dr. Christine Chung of Moffitt Cancer Center. Interested parties can view the poster on Cue Biopharma’s website after the event.

On May 11, 2022, Cue Biopharma announced that the FDA accepted its IND application for CUE-102, initiating a Phase 1 trial for the treatment of WT1-positive recurrent/metastatic cancers, including gastric and pancreatic cancers. The trial will start at a dose of 1 mg/kg, which is expected to streamline the dose escalation process, potentially reducing time and costs. CUE-102 builds on the CUE-100 series biologics, which selectively engage T cells, and follows the encouraging results from the CUE-101 trial.